Page 32 - Coronavirus Vaccine

LIVE: Union Cabinet approves policy on long-term leasing of Railways' land

300 cargo terminals will be developed in 5 years, says Union Minister Anurag Thakur on Union Cabinet decisions

High-risk groups priority for latest adapted Covid-19 vaccines: ECDC

The European Centre for Disease Prevention and Control said that individuals in high-risk groups and healthcare workers should be prioritised when the latest adapted Covid-19 vaccines are rolled out.

Data story: India logs 5,379 new Covid cases; death toll at 528,057

India has so far administered 2,139,149,934 vaccine doses

Top headlines: India's first nasal vaccine for Covid-19; new seat belt rule

Business Standard brings you the top headlines at this hour

India's first nasal vaccine for Covid-19 gets DCGI nod for emergency use

Bharat Biotech's iNCOVACC cleared for 2-dose regimen

Updated Covid boosters ready in US this week, says White House

US health officials said on Tuesday that the vaccine is moving closer to an annual jab, as with flu shots

Intranasal Covid vaccine will be global game changer: Bharat Biotech MD

Phase III trials were conducted for safety, and immunogenicity in about 3,100 subjects, in 14 trial sites across India

Bharat Biotech's intranasal Covid vaccine gets DCGI's nod for emergency use

The Drugs Controller General of India (DCGI) on Tuesday approved Bharat Biotech's intranasal Covid vaccine for restricted emergency use in those aged above 18 years. "Big Boost to India's Fight Against COVID-19! Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation," Union Health Minister Mansukh Mandaviya tweeted. He said this step will further strengthen "our collective fight" against the pandemic. India has harnessed its science, research and development (R&D), and human resources in the fight against COVID-19 under Prime Minister Narendra Modi's leadership, he said. "With the science-driven approach & Sabka Prayas, we will defeat COVID-19," Mandaviya also said. The Hyderabad-based firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse

Fight against Covid-19: Here is a list of vaccines approved in India

Besides Bharat Biotech's nasal vaccine, India has 13 vaccines to fight against Covid-19. Two have been approved for manufacturing, while 11 have been approved for emergency use

Top headlines:India gets intranasal Covid vax; Moody's retains India rating

The global ratings agency said it will maintain its long-term sovereign debt credit rating and outlook on Asia's third largest economy

Heart inflammation risk after Covid-19 booster rare in young men: Study

The risk of developing myocarditis among males ages 16 to 19 years are about one in 15,000 after the third dose of the Pfizer-BioNTech Covid-19 vaccine, however the cases are rare and mild.

Data story: India logs 4,417 new Covid cases; active tally at 52,336

India has added 48,277 cases in the past 7 days

World's first coronavirus vaccine you can inhale approved in China

China's National Medical Products Administration approved CanSino's Ad5-nCoV for emergency use as a booster vaccine

India will not witness a fourth wave of Covid-19, say health experts

Dr Pragya Yadav, senior scientist at the government's ICMR-NIV institute in Pune, said there is no cause for worry until new variants of concern (VoCs) spread in India

Data story: India logs 5,910 new Covid cases; death toll at 528,007

India has added 46,722 cases in the past 7 days

Data story: India logs 6,799 new Covid cases; active tally at 55,114

India has added 57,419 cases in the past 7 days

UK approves second 'bivalent' booster for Omicron and Covid strain

The UK health authorities on Saturday approved a second bivalent vaccine to be used as a booster vaccine to target both the Omicron and original strain of COVID-19. The Medicines and Healthcare products Regulatory Agency (MHRA) said the updated booster vaccine made by Pfizer/BioNTech was found to meet its standards of safety, quality and effectiveness. The jab targeting two coronavirus variants has been approved for use in individuals aged 12 years and above. In each dose of the booster vaccine called Comirnaty bivalent Original/Omicron, half of the vaccine (15 micrograms) targets the original virus strain and the other half (15 micrograms) targets Omicron (BA.1). The clinical trial of the Pfizer/BioNTech bivalent vaccine showed a strong immune response against the Omicron BA.1 variant as well as the original strain, said Dr June Raine, MHRA Chief Executive. Bivalent vaccines are helping us to meet the challenge of an ever-evolving virus, to help protect people against COVID-19 ...

Only 25 % people in Odisha took Covid-19 precaution dose, says official

The Odisha government appealed to the people on Saturday to take the precaution dose against coronavirus as soon as possible as few weeks are left for the period of free jabs and only a quarter of the targeted population got vaccinated with the third shot. A total of 80.90 lakh people, including frontline workers and those in the 18-60 age group and above 60 years, have taken the precaution dose, Health Director Bijay Panigrahi said at a press briefing in Bhubaneswar. "Around 25 per cent of the targeted population have taken the precaution dose while many are yet to take the jab," he said, adding that 23 lakh beneficiaries of the first shot had the second one due even now. Panigrahi appealed to people to take the precaution dose by September 30, the deadline set by the Union government for giving free jabs at public healthcare institutions. The COVID-19 tally rose to 13,28,244 on Saturday as 174 more people, including 13 children, tested positive for the infection, a health bulleti

Over 2.01 bn Covid vaccine doses provided under vaccination drive: Centre

Union Government provided over 201.36 crore vaccines to states and UTs in the fight against Covid-19 and of these more than 5.47 crore doses are still available, according to official data

New Covid boosters for Omicron strains to roll out soon as CDC gives nod

New COVID-19 boosters that target today's most common omicron strains are set to begin soon after the Centers for Disease Control and Prevention endorsed the updated shots. The decision by CDC Director Rochelle Walensky on Thursday came shortly after the agency's advisers said if enough people roll up their sleeves, the shots could blunt a winter surge. They can help restore protection that has waned since previous vaccination and were designed to provide broader protection, she said in a statement. The tweaked shots made by Pfizer and rival Moderna offer Americans a chance to get the most up-to-date protection at yet another critical period in the pandemic. They're combination or bivalent shots half the original vaccine and half protection against the BA.4 and BA.5 omicron versions now causing nearly all COVID-19 infections. The CDC's advisers struggled with who should get the new booster and when because only a similarly tweaked vaccine, not the exact recipe, has been studied in